Alexion Pharmaceuticals Inc

ALXN 
(NASDAQ) 
 
$ 117.93 <%= Resources.Global.txtUp %>
Updated 13/06/2019
Change % 0.59% Stock price increasing
Change 0.69 Stock price increasing
Volume 747,063
High $ 118.96
Low $ 116.81
Open $ 117.34
ISIN
Prev close $ 117.24
# of shares 224.24M
Market cap 26,444M USD
Intraday

Market closed
Alexion Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  117.93 -0.4% Stock price decreasing -10.3% Stock price decreasing -13.3% Stock price decreasing 7.8% Stock price increasing -3.0% Stock price decreasing
Powered by TradingView

News about Alexion Pharmaceuticals Inc

  • English
  • Regulatory news

Company profile

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. Next-generation Ultomiris was recently approved in paroxysmal nocturnal hemoglobinuria. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need and complement-mediated disorders.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 04:32:48
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB4 - 2019-06-16 05:32:48 - 2019-06-16 04:32:48 - 1000 - Website: OKAY